- Home
- MTEK vs CRIS Comparison
MTEK vs CRIS Comparison
Compare MTEK & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MTEK | CRIS |
|---|---|---|
| Founded | 2008 | 2000 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6M | 12.9M |
| IPO Year | 2022 | 2000 |
Fundamental Metrics
Financial Performance| Metric | MTEK | CRIS |
|---|---|---|
| Price | $1.67 | $0.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 88.0K | ★ 1.2M |
| Earning Date | 09-26-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,375,716.00 | ★ $11,650,000.00 |
| Revenue This Year | N/A | $6.13 |
| Revenue Next Year | N/A | $7.86 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.56 |
| 52 Week Low | $1.03 | $0.77 |
| 52 Week High | $4.27 | $3.57 |
Technical Indicators
Market Signals| Indicator | MTEK | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 64.42 | 40.58 |
| Support Level | $1.51 | $0.87 |
| Resistance Level | $1.89 | $0.98 |
| Average True Range (ATR) | 0.14 | 0.10 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 65.74 | 49.26 |
Price Performance
Historical ComparisonAbout MTEK Maris-Tech Ltd.
Maris Tech Ltd is a business-to-business approach, or B2B provider of remote video, audio, telemetry acquisition, distribution, and sharing solutions and products, using high-end digital video, audio, and wireless communication technologies. It designs, develops, manufactures and commercially sells miniature intelligent video and audio surveillance and communication systems, which are offered as products and solutions for the professional as well as the civilian and home security markets.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.